Researchers have created wheat that is resistant to a common disease, using advanced gene editing methods.

Seeds of hope: Chinese researchers led by Caixia Gao have developed genetically modified wheat far more able to withstand powdery mildew.

Advanced genome-editing techniques have been used to create a strain of wheat resistant to a destructive fungal pathogencalled powdery mildewthat is a major bane to the worlds top food source, according to scientists at one of Chinas leading centers for agricultural research.

To stop the mildew, researchers at the Chinese Academy of Sciences deleted genes that encode proteins that repress defenses against the mildew. The work promises to someday make wheat more resistant to the disease, which is typically controlled through the heavy use of fungicides. It also represents an important achievement in using genome editing tools to engineer food crops without inserting foreign genesa flashpoint for opposition to genetically modified crops.

The gene-deletion trick is particularly tough to do in wheat because the plant has a hexaploid genome, that is, it has six copies of each of its seven chromosomes, multiple genes must be disabled or the trait will not be changed. Using gene-editing tools known as TALENs and CRISPR, the researchers were able to do that without changing anything else or adding genes from other organisms.

We now caught all three copies, and only by knocking out all three copies can we get this [mildew]-resistant phenotype, says Caixia Gao, who heads a gene-editing research group at the State Key Laboratory of Plant Cell and Chromosome Engineering at the Institute of Genetics and Developmental Biology in Beijing.

A paper describing the results appears in Nature Biotechnology.

This is very, very interesting; it is quite an accomplishment to knock out all three genes at the same time, says Xing-Wang Deng, who heads a joint research center for plant molecular genetics and agricultural biotech at Peking University and Yale. And this could be considered as a nontransgenic technology, so that can be very significant. I hope the government would not consider this transgenic, because the end result is no different than a natural mutation.

There are currently no commercially planted varieties of genetically modified wheat anywhere in the world. And while many farmers are clamoring for access to such strains, genetically modified wheat remains highly controversial. Indeed, its not clear is whether Gaos promising strain of wheat will make it out of the greenhouses in Beijing.

Gao says she has filed a global patent on the technology, suggesting it could be licensed. But there are no field trials planned yet. While China has greatly increased investments in basic biotech research, including for genetically modified crops, no new field trials of genetically engineered plants have been approved in more than a year as the government tries to mollify public concern over GMOs.

Read more:
Chinese Researchers Stop Wheat Disease with Gene Editing

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

21-Jul-2014

Contact: Harry Dayantis h.dayantis@ucl.ac.uk 44-020-310-83844 University College London

A rare gene variant discovered by UCL (University College London) scientists is associated with an increased risk of developing schizophrenia, bipolar disorder and alcoholism, confirms new research.

People with the variant are around 2 to 3 times more likely to develop schizophrenia or alcohol dependence, reports a new UCL study. The variant, which is found in approximately one in every 200 people, is also associated with a threefold risk of developing bipolar disorder, as previously shown by the same UCL group.

The research, published in Psychiatric Genetics, is based on genetic analysis of 4,971 people diagnosed with one of the three disorders compared with 1,309 healthy controls. It found that people with the variant of the GRM3 gene, thought to be important in brain signalling, were at increased risk of developing bipolar disorder, schizophrenia and alcohol dependence.

GRM3's association with schizophrenia was also confirmed by a global study involving a consortium of over 200 institutions including UCL. The research, published in Nature, involved searching the genomes of 36,989 people with schizophrenia and 113,075 healthy subjects from across the world. 108 different genetic locations were found to be associated with the disease, but GRM3 is the only one for which a specific mutation responsible has been identified.

"We could be looking at the next big drug target for treating mental illness," says Professor David Curtis (UCL Psychiatry), co-author on both papers. "The work opens up new ways to prevent and treat mental illnesses by revealing the mechanisms involved in their development. The result for GRM3 from the consortium is particularly compelling, as the odds of this occurring by chance are only one in a billion."

At present, schizophrenia is treated with drugs that reduce the activity of the chemical dopamine. Dopamine is important for transmitting messages between brain cells, but over-active dopamine signalling may cause parts of the brain that are supposed to be separate to communicate with each other. For example, some scientists suspect that such signalling between the speech and hearing centres of the brain may explain why people with schizophrenia 'hear voices'.

Yet dopamine is not the only chemical that brain cells use to communicate with each other. Glutamate is also involved and GRM3 codes for a protein which brain cells use to detect glutamate. Brain cell activation is controlled by calcium 'channels'. The latest research implicates both glutamate transmission and calcium channels in schizophrenia development.

Original post:
Gene variant linked to schizophrenia, bipolar disorder and alcoholism

Recommendation and review posted by Bethany Smith

5 facts about genetic engineering
how its done , what #39;s going on and more all in this video. I hope you enjoyed this video. This is the first of many science videos I #39;m now planning on making.Please subscribe to feel the buzz.

By: lightning burnzzz

Read more here:
5 facts about genetic engineering - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

21-Jul-2014

Contact: Kathryn Ruehle kruehle@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, July 21, 2014In Alzheimer's disease, accumulation of amyloid plaque in the brain is believed to play an important role in many characteristic disease symptoms, including memory loss and other mental state changes. But how these plaque deposits affect brain function is not well understood. Important new study results showing that plaque buildup in one area of the brain can negatively affect metabolism in a more distant brain region have been published in Brain Connectivity, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Brain Connectivity website at http://online.liebertpub.com/doi/full/10.1089/brain.2013.0212 until August 21, 2014.

As part of a special issue focused on Alzheimer's disease, Elisabeth Klupp and coauthors, Technische Universtt Mnchen (Munich and Garching, Germany) and University Hospital of Cologne, Germany, present the results of an imaging-based study demonstrating that amyloid buildup in one brain region can impair brain cell metabolism and activity another in remote brain region not affected by amyloid plaque accumulation. The regions studied were part of the same functional network but are located remotely from each other in the brain. The authors suggest this long-distance effect may be the result of diminished neuronal signals originating from the amyloid-affected brain region to the remote amyloid-unaffected brain region. The findings are discussed in the article "In Alzheimer's Disease, Hypometabolism in Low-Amyloid Brain Regions May Be a Functional Consequence of Pathologies in Connected Brain Regions."

"This research may be an important new discovery that links two important hypotheses in Alzheimer's disease research: the amyloid buildup hypothesis and the network degenerating hypothesis," says Christopher Pawela, PhD, Co-Editor-in-Chief and Assistant Professor, Medical College of Wisconsin.

###

About the Journal

Brain Connectivity is the essential peer-reviewed journal covering groundbreaking findings in the rapidly advancing field of connectivity research at the systems and network levels. Published 10 times per year in print and online, the Journal is under the leadership of Founding and Co-Editors-in-Chief Christopher Pawela, PhD, Assistant Professor, Medical College of Wisconsin, and Bharat Biswal, PhD, Chair of Biomedical Engineering, New Jersey Institute of Technology. It includes original peer-reviewed papers, review articles, point-counterpoint discussions on controversies in the field, and a product/technology review section. To ensure that scientific findings are rapidly disseminated, articles are published Instant Online within 72 hours of acceptance, with fully typeset, fast-track publication within 4 weeks. Tables of content and a sample issue may be viewed on the Brain Connectivity website at http://www.liebertpub.com/brain.

About the Publisher

See the original post:
Can amyloid plaque in Alzheimer's disease affect remote regions of the brain?

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

21-Jul-2014

Contact: Kathryn Ruehle kruehle@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY -- The Human Microbiome Project (HMP) is a global initiative to identify and characterize the microorganisms present at multiple sites in the human body. An international team of researchers reports on new ways to harness the results of the HMP and discusses how changes in the microbiome might affect human health, disease, immunity, and importantly, the safety and effectiveness of drug treatment in a Review article that is part of the special issue "OMICS in Africa: Moving 21st Century Integrative Biology from Lab to Village to Innovation Ecosystems," of OMICS: A Journal of Integrative Biology, the peer-reviewed interdisciplinary journal published by Mary Ann Liebert, Inc., publishers. The issue is available on the OMICS website.

In the article "Pharmacomicrobiomics: The Impact of Human Microbiome Variations on Systems Pharmacology and Personalized Therapeutics," senior author Ramy Karam Aziz and coauthors propose a "microbiome cloud model" to understand the variation in an individual's microbiome composition within and between individuals and how that variability makes it difficult to define the human microbiome. They present detailed examples of microbiome changes related to colorectal cancer, use of antibiotics, and pharmacomicrobiomics or drug-microbiome interactions in relation to personalized healthcare.

In the Commentary "Translating Biotechnology to Knowledge-Based Innovation, Peace, and Development? Deploy a Science Peace CorpsAn Open Letter to World Leaders," Nezih Hekim, SANKO University, Turkey and coauthors in 15 countries from around the world joined forces with OMICS Editor-in-Chief Vural zdemir, MD, PhD, DABCP Gaziantep University, Faculty of Communications, School of Journalism, Gaziantep Turkey, to call for the creation of a global Science Peace Corps. This idea and initiative would entail volunteer work in life sciences translational research for no less than 6 weeks and up to 2 years in any region of the world. The topics could relate to all fields of medicine "as long as they are linked to potential or concrete endpoints in development, foreign policy and/or peace scholarship domains." The authors describe the proposed Science Peace Corps as a "new instrument in the global science governance toolbox" that would advance "the emerging concept of 'one health'encompassing human, environmental, plant, microbial, ecosystem, and planet health."

Original research articles in this special issue cover topics of relevance to Africa such as HIV transmission and epidemiology, maternal health, malaria, common complex diseases such as deafness, and policy action for sickle cell anemia that is greatly impacting the African populations.

African science and knowledge-based innovation are central to a deep understanding of pathophysiology, prevention and treatment of human diseases, discovery and development of novel diagnostics, as well as ecosystem health. OMICS Editor-in-Chief Vural zdemir summarizes the special issue as "very much in the spirit of the integration we seek to achieve in the Journal across biotechnologies, their variegated applications in life sciences, and between technology and global society, so that knowledge-based innovations can responsibly integrate at a community level."

###

About the Journal

View original post here:
New research from Africa on pharmacomicrobiomics

Recommendation and review posted by Bethany Smith

The recent decision of the Genetic Engineering Appraisal Committee (GEAC) to allow field trials of GM rice, mustard, cotton, chickpea and brinjal has been met with strong opposition from farmers groups and environmental activists.

Seeking the intervention of Union Environment and Forests Minister Prakash Javdekar, the Bhartiya Kisan Union has asked for annulment of the approvals.

Questioning the need for release of genetically modified organisms (GMOs) in the fields, the BKU leaders said they were concerned over the nations seed and food sovereignty.

This is because most genes as well as transgenic processes are already patented and these Intellectual Property Rights work for the monopolistic benefit of the profiteering multinational corporations. The ease with which a transgenic technology allows corporations to claim ownership rights over seeds makes it attractive to them to hype why the world needs GMOs and seek control over entire food chains from production to marketing jeopardising the livelihood security of farmers, BKU leaders Naresh Tikait, Dharmendra Malik and Yudhveer Singh said in a letter to the Minister.

In a separate letter to Mr. Javadekar, the Coalition for GM-free India said the GEAC approvals came at a time the Supreme Court was about to pronounce its orders on the issue of field trials of GM crops, based on the recommendations of the Courts Technical Expert Committee (TEC). Realising the potential of field trials to contaminate the seed, food supply chains and environment, and owing to the lack of a proper regulatory system, the TEC has recommended a moratorium on open-air field trials.

It is ironical that the BJP manifesto promise of not allowing GM foods in the country without full scientific evaluation of their long-term effects on soil, production and biological impact on consumers is the main subject for this PIL petition in the Supreme Court. It was pending the decision of the apex court that former Environment Minister Jayanthi Natarajan had stayed GEAC meetings... The last time the GEAC approved some GMOs for open- air field testing, prominent BJP leaders had condemned the move, Rajesh Krishnan of the coalition said.

More:
Dont allow field trials of GM crops: farmers, activists

Recommendation and review posted by Bethany Smith

July 21, 2014

redOrbit Staff & Wire Reports Your Universe Online

The majority of the genetic risks for developing autism can be traced to common versions of genes, not rare variants or spontaneous mutations, according to the results of a National Institutes of Health-funded study that appeared in Sundays edition of the journal Nature Genetics.

In total, approximately 52 percent of the risk for autism was traced to common or rare inherited variation, while spontaneous mutations comprised just 2.6 percent of the overall risk, a team of researchers led by Dr. Joseph Buxbaum of the Icahn School of Medicine at Mount Sinai (ISMMS) in New York reported in the paper.

In addition, heritability was also found to outpace other risk factors. The study is said to be the largest of its kind, and the Population-Based-Autism Genetics and Environment Study (PAGES) Consortium researchers behind the paper claim that their findings indicate that inheritability outweighs environmental risk.

Dr. Buxbaum and his colleagues conducted a rigorous analysis of DNA sequence variations from an ongoing, comprehensive study of autism in Sweden. Health registry data from 3,000 patients, some of whom were autistic individuals and some belonging to a control group, was analyzed for the purposes of the study.

We show very clearly that inherited common variants comprise the bulk of the risk that sets up susceptibility to autism, explained Dr. Buxbaum, is an ISMMS professor as well as the director of the Seaver Autism Center for Research and Treatment. But while families can be genetically loaded for autism risk, it may take additional rare genetic factors to actually produce the disorder in a particular family member.

Thanks to the boost in statistical power that comes with ample sample size, autism geneticists can now detect common as well as rare genetic variation associated with risk, added Dr. Thomas R. Insel, director of the NIHs National Institute of Mental Health (NIMH). Knowing the nature of the genetic risk will reveal clues to the molecular roots of the disorder. Common variation may be more important than we thought.

While autism is believed to be caused by the interplay of genetic and other factors, scientists have never been able to reach a consensus on the relative contributions of those factors, the researchers said. Recent research has uncovered mounting evidence that the genomes of autistic men and women are likely to contain de novo mutations rare, spontaneous mutations with strong effects that are largely to blame for certain cases of the ailment.

Many people have been focusing on de novo mutations, such as the ones that can occur in the sperm of an older father. While we find these mutations are also key contributors, it is important to know that there is underlying risk in the family genetic architecture itself, Dr. Buxbaum said.

Read more from the original source:
Common Variants Responsible For Most Genetic Risk Of Autism

Recommendation and review posted by Bethany Smith

By SETH BORENSTEIN AP Science Writer

WASHINGTON (AP) - Scientists have linked more than 100 spots in our DNA to the risk of developing schizophrenia, casting light on the mystery of what makes the disease tick.

Such work could eventually point to new treatments, although they are many years away. Already, the new results provide the first hard genetic evidence to bolster a theory connecting the immune system to the disease.

More than 100 researchers from around the world collaborated in the biggest-ever genomic mapping of schizophrenia, for which scientists had previously uncovered only about a couple of dozen risk-related genes.

The study included the genetic codes of more than 150,000 people - nearly 37,000 of them diagnosed with the disease. Researchers found 108 genetic markers for risk of getting the disease, 83 of them not previously reported. And scientists say there are still likely more to be found.

"It's a genetic revelation; schizophrenia has been a mystery," said study co-author Steve McCarroll, director of genetics for the Broad Institute of MIT and Harvard. "Results like this give you things to work on. It takes it out of the zone of guesses about which genes are relevant."

The results were released Monday by the journal Nature. It takes large studies to ferret out genes related to schizophrenia risk because each gene generally has only a very weak effect.

Schizophrenia is a debilitating mental disorder that makes it hard to tell the difference between what is real and not real, and affects about one out of every 100 people. Studies estimate that it costs $60 billion in the U.S. each year. Scientists have long known that genes play a part, and this work further confirms that.

The results are a "big step" toward finding drug therapies, said study lead author Dr. Michael O'Donovan, deputy director of the MRC Centre for Neuropsychiatric Genetics and Genomics at Cardiff University School of Medicine in Wales. While 108 genetic markers are a lot, the study authors say they tend to implicate a narrower group of biological functions, giving some but not too many hints for scientists to pursue.

"It's a map or maze. It's telling you were to start, it's not telling you where to end," O'Donovan said.

Read the original post:
Genetic mapping triggers new hope on schizophrenia - NBC40.net

Recommendation and review posted by Bethany Smith

Most of the genetic risk for autism appears to come from common gene variants rather than spontaneous gene mutations, according to a new study.

Researchers compared about 3,000 people in Sweden with and without autism and found that about 52 percent of autism was linked to common gene variants and rare inherited variations. Spontaneous genetic mutations accounted for only 2.6 percent of autism risk.

The investigators also found that genetics seem to play a stronger role in autism risk than environmental factors, according to the study funded by the U.S. National Institutes of Health.

The study, which the researchers said was the largest of its kind to date, was published in the July 20 issue of the journal Nature Genetics.

"From this study, we can see that genetics plays a major role in the development of autism compared to environmental risk factors, making autism more like height than we thought -- many small risk factors add up, each pushing a person further out on the spectrum," co-lead investigator Kathryn Roeder, professor of statistics and computational biology at Carnegie Mellon University in Pittsburgh, said in a university news release.

Play Video

New research shows that 1 out of 68 children in the U.S. is afflicted with some form of autism - up 30 percent from two years ago. Lesley Stahl o...

Autism spectrum disorders describe a range of developmental disabilities that can cause social, communication and behavioral difficulties. About 1 in 68 U.S. children has an autism spectrum disorder, the U.S. Centers for Disease Control and Prevention estimates.

"Genetic variation likely accounts for roughly 60 percent of the liability for autism, with common variants comprising the bulk of its genetic architecture," co-lead investigator Joseph Buxbaum, of the Icahn School of Medicine at Mount Sinai in New York City, said in a news release from the U.S. National Institute of Mental Health (NIMH).

"Although each exerts just a tiny effect individually, these common variations in the genetic code add up to substantial impact, taken together," explained Buxbaum.

The rest is here:
Autism risk linked to common gene variants

Recommendation and review posted by Bethany Smith

Let #39;s Play The Sims 3 - Perfect Genetics Challenge: Cowgirl and Horse Edition Episode 22
Come join me on my latest journey into the complex world of sims 3 genetics, as I try to get perfect foals and perfect children. Will I succeed in getting pe...

By: GamerGirlsNetwork

See the original post here:
Let's Play The Sims 3 - Perfect Genetics Challenge: Cowgirl and Horse Edition Episode 22 - Video

Recommendation and review posted by Bethany Smith

Risha Nahar Lulla Genetics Department KIMS
Risha Nahar Lulla Head of Genetics Department KIMS.

By: hybiztv

Visit link:
Risha Nahar Lulla Genetics Department KIMS - Video

Recommendation and review posted by Bethany Smith

The Truth About Genetics
This video is about genetics and how important a role they play in your physique goals. With IFBB Pro and AG CEO Chris Johnson. Military Grade Supplements fo...

By: AdvancedGeneticsTV

Original post:
The Truth About Genetics - Video

Recommendation and review posted by Bethany Smith

Robert Sapolsky - Genetics and epigenetics
4. Molecular Genetics I http://www.youtube.com/watch?v=_dRXA1_e30o 01-25-47 - 01-32-24.

By: Mind.Blown

View post:
Robert Sapolsky - Genetics and epigenetics - Video

Recommendation and review posted by Bethany Smith

Robert Sapolsky - Clarifying the genetics soundbytes
4. Molecular Genetics I http://www.youtube.com/watch?v=_dRXA1_e30o 00-47-18 - 00-50-46.

By: Mind.Blown

Go here to read the rest:
Robert Sapolsky - Clarifying the genetics soundbytes - Video

Recommendation and review posted by Bethany Smith

DNA Fingerprinting, from Useful Genetics
A sample video lecture on DNA fingerprinting, from the Coursera course Useful Genetics.

By: Rosie Redfield

Continued here:
DNA Fingerprinting, from Useful Genetics - Video

Recommendation and review posted by Bethany Smith

By RTT News, July 21, 2014, 08:04:00 AM EDT

(RTTNews.com) - Cancer Genetics, Inc. ( CGIX ), an emerging leader in DNA-based cancer diagnostics, Monday announced the signing of a definitive agreement to acquire privately held Gentris Corp., a provider of clinical pharmacogenomics solutions, next-generation sequencing, and biomarker testing.

Cancer Genetics said it expects the acquisition to add approximately $5 to $6 million in annual sales, and add substantially to it biopharma revenue backlog and capabilities.

Gentris provides genomic testing and pharmacogenomics services and has operations in Raleigh (Research Triangle Park), North Carolina and Shanghai, China.

With the deal, the company said it will now be positioned to provide global services for genomic and biomarker testing for biotech and pharmaceutical companies by leveraging both it's unique tests and comprehensive oncology services.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Read this article:
Cancer Genetics To Buy Pharmacogenomics Firm Gentris - Quick Facts

Recommendation and review posted by Bethany Smith

Published 18 July 2014

ViaCyte a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, announced that it has filed an Investigational New Drug application (IND) with the United States Food and Drug Administration (FDA) seeking to initiate a Phase 1/2 clinical trial in patients with type 1 diabetes.

The trial would evaluate the safety and efficacy of ViaCyte's VC-01 product candidate, a stem cell-derived, encapsulated cell replacement therapy. In a related development, ViaCyte submitted a Medical Device Master File (called MAF) to the FDA in support of the Encaptra drug delivery system, the device component of the VC-01 product candidate.

"The filing of this IND represents the culmination of many years of research and development by a dedicated team focused on developing a cell replacement therapy for patients with type 1 diabetes and advancing our VC-01 product candidate to human clinical trials," said Paul Laikind, Ph.D., President and Chief Executive Officer of ViaCyte.

"The ViaCyte team has been assisted and supported by the California Institute for Regenerative Medicine (CIRM) a leading organization focused on advancing the field of stem cell-based technologies, and JDRF, the leading advocacy organization for patients with type 1 diabetes," added Dr. Laikind.

ViaCyte's VC-01 product candidate consists of pancreatic progenitor cells, called PEC-01 cells, which are derived from a proprietary human embryonic stem cell line. These cells are then encapsulated by use of ViaCyte's Encaptra device.

When implanted under the skin, the PEC-01 cells are designed to mature and further differentiate into insulin-producing beta and other endocrine cells that regulate blood glucose in a manner similar or identical to the normal islets that comprise the endocrine pancreas.

Based on a pre-IND meeting with the FDA and subsequent consultations, ViaCyte is proposing to initiate clinical evaluation of the VC-01 product candidate directly in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function.

In addition to evaluating the safety of the product candidate in these patients, the study is designed to demonstrate the effectiveness of the VC-01 product candidate in replacing lost endocrine function that is central to the disease.

In the proposed clinical trial, insulin production from the VC-01 implant would be assessed by measuring C-peptide, a biomarker for insulin produced by beta cells that is expected to provide a sensitive measure of efficacy in these patients.

Link:
ViaCyte files investigational new drug application and device master file with FDA for novel cell replacement therapy ...

Recommendation and review posted by simmons

According to President George W. Bush, the stem cell research bill, which Bush vetoed on July 20, would "support the taking of innocent human life in the hope of finding medical benefits for others... it crosses a moral boundary that our decent society needs to respect."

Point taken. I just need to ask two questions. Why is "killing" stem cells, which have no proven brain function or EEG (electroencephalogram) pattern and nothing to "live" for, crossing a moral boundary? It seems to the president that it is not crossing a moral boundary to kill (no quotes, we're definitely killing in this case) innocent civilian Iraqis in the hope of benefiting the greater population of Iraq and the U.S.

According to leading scientists in the field, our society has defined death as the loss of the cerebral EEG pattern. Some scientists have also thought that the acquisition of the human EEG, which occurs at about 27 weeks of life, should be defined as when a human life begins. This view has been put forth most concretely by scientists Morowitz and Trefil (1992).

View post:
Monday, July 21, 2014 12:00 am

Recommendation and review posted by simmons

Geoffrey Box, MD - Department of Urology
Dr. Box discusses his educational background and approach to personalized medicine at Ohio State #39;s Wexner Medical Center. Dr. Geoffrey N. Box is assistant pr...

By: osumedicalcenter

View post:
Geoffrey Box, MD - Department of Urology - Video

Recommendation and review posted by sam

Overview of CSIL
General overview discussion about the CSIL program.

By: Spinal Cord Injury BC

Read the original post:
Overview of CSIL - Video

Recommendation and review posted by sam

Pros of Being on CSIL
A brief discussion on the the more common pros of being on the CSIL program.

By: Spinal Cord Injury BC

Originally posted here:
Pros of Being on CSIL - Video

Recommendation and review posted by sam

Meeting your case manager
A brief discussion on when you meet your case manager during the application process for the CSIL program.

By: Spinal Cord Injury BC

Here is the original post:
Meeting your case manager - Video

Recommendation and review posted by sam

Allowable expenses
Paul shares on what you can and cannot claim under the CSIL funds.

By: Spinal Cord Injury BC

Read more here:
Allowable expenses - Video

Recommendation and review posted by sam

The employer package
Paul explains what you will receive in the mail as part of your employer package. This includes the your CSIL contract with the health authority.

By: Spinal Cord Injury BC

Continued here:
The employer package - Video

Recommendation and review posted by sam

Stem Cell Therapy in Cardiac Disease - Charles Murry, MD, Ph.D.
How can we harness the power of stem cells to repair the heart or other damaged organs? Dr. Chuck Murry, Dept. of Pathology; Director, Center for Cardiovascular Biology at the University of...

By: UWTV

See the article here:
Stem Cell Therapy in Cardiac Disease - Charles Murry, MD, Ph.D. - Video

Recommendation and review posted by simmons